Abstract
Since their discovery in the late 1980s, Hepatocyte growth factor (HGF) and its receptor, c-MET, have become the focus of intense scrutiny as regards their role in cancer and metastasis [1, 2]. HGF is now known to be a potent morphogen that can regulate tissue and organ regeneration and modulate cell morphology, it is a motogen that can stimulate cell motility and migration, and is a mitogen able to regulate cell growth and death and is a powerful angiogenic and lymphangiogenic factor [3-5]. The diverse range of functions that can be ascribed to HGF/c-MET is transmitted via a variety of cell signaling pathways. This review will focus on recent work demonstrating the importance of HGF/c-MET in regulating these signaling events, how they are related to cancer metastasis and where they may be targeted for patient intervention.
Keywords: Cancer, HGF, Metastasis, Signaling, c-MET, intracellular signalling, Grb2/SOS, Gab1, PI3 kinase, Stat3, Wnt signaling, Rho/Rac, Protein Kinase C, protein tyrosine phosphates, MAPK, mTOR, ERK, Mcl-1, RAS, MEK, LKB1, Cdc42, Mig6, Phospholipase C g-, cRaf, Catenin, Paxillin, FAK
Current Signal Transduction Therapy
Title: Hepatocyte Growth Factor Signaling in Cancer Metastasis
Volume: 6 Issue: 2
Author(s): Tracey A. Martin, Malcolm D. Mason and Wen G. Jiang
Affiliation:
Keywords: Cancer, HGF, Metastasis, Signaling, c-MET, intracellular signalling, Grb2/SOS, Gab1, PI3 kinase, Stat3, Wnt signaling, Rho/Rac, Protein Kinase C, protein tyrosine phosphates, MAPK, mTOR, ERK, Mcl-1, RAS, MEK, LKB1, Cdc42, Mig6, Phospholipase C g-, cRaf, Catenin, Paxillin, FAK
Abstract: Since their discovery in the late 1980s, Hepatocyte growth factor (HGF) and its receptor, c-MET, have become the focus of intense scrutiny as regards their role in cancer and metastasis [1, 2]. HGF is now known to be a potent morphogen that can regulate tissue and organ regeneration and modulate cell morphology, it is a motogen that can stimulate cell motility and migration, and is a mitogen able to regulate cell growth and death and is a powerful angiogenic and lymphangiogenic factor [3-5]. The diverse range of functions that can be ascribed to HGF/c-MET is transmitted via a variety of cell signaling pathways. This review will focus on recent work demonstrating the importance of HGF/c-MET in regulating these signaling events, how they are related to cancer metastasis and where they may be targeted for patient intervention.
Export Options
About this article
Cite this article as:
A. Martin Tracey, D. Mason Malcolm and G. Jiang Wen, Hepatocyte Growth Factor Signaling in Cancer Metastasis, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795659991
DOI https://dx.doi.org/10.2174/157436211795659991 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Endometrial Cancer: Genetic, Metabolic Characteristics, Therapeutic Strategies and Nanomedicine
Current Medicinal Chemistry Advances of Paclitaxel Formulations Based on Nanosystem Delivery Technology
Mini-Reviews in Medicinal Chemistry Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Autologous Formalin-Fixed Tumor Vaccine
Current Pharmaceutical Design Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Current Clinical Pharmacology Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Eupatilin Inhibits the Proliferation and Migration of Prostate Cancer Cells through Modulation of PTEN and NF-κB Signaling
Anti-Cancer Agents in Medicinal Chemistry DMBA- Induced Breast Cancer: A Hormonal Camouflage
Current Cancer Therapy Reviews The Role of Hypoxia in Endometrial Cancer
Current Pharmaceutical Biotechnology Heterogeneity in the Pathology and Molecular Biology of Breast Cancer
Current Genomics Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors
Current Drug Targets Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Privileged Scaffolds Targeting Bromodomain-containing Protein 4
Current Topics in Medicinal Chemistry The Immunoregulatory Activity of Mesenchymal Stem Cells: ‘State of Art’ and ‘Future Avenues’
Current Medicinal Chemistry